Latest News

Details Of Value-Based Pricing System For New Medicines Still Being Hammered Out

The Government has confirmed that it will bring in a value-based system for deciding the price of new medicines but has yet to decide which additional factors, beyond cost and clinical effectiveness, will become part of the equation.

Paying higher prices for new drugs for serious diseases that currently have the "highest unmet need" was generally welcomed, according to a summary of responses to the Government’s consultation on its proposals, which was published today (18 July 2011).

However, there was concern that introducing a "burden of illness" factor in determining the price of a drug could create a hierarchy of disease, which was not so popular.

The Government, as part of its next moves in developing the system, plans to look in more detail at the idea that issues such as the impact of disease on carers and how lack of treatment can affect a patient’s ability to work should also influence drug prices.

To read the full story click here.

Extract taken from PJ Online